Oral Tranexamic Acid Dosing for Heavy Menstrual Bleeding
For heavy menstrual bleeding, the standard oral tranexamic acid dose is 3.9-4 grams per day (typically 1.3 grams three times daily or 650 mg 6 times daily) taken for 4-5 days starting from the first day of menstruation, and this regimen should NOT be used concurrently with combined oral contraceptives due to increased thrombotic risk. 1, 2
Critical Safety Concern: Contraceptive Interaction
Avoid concomitant use of tranexamic acid with hormonal contraceptives, as both are prothrombotic agents and combined use significantly increases the risk of venous thromboembolism. 3 The FDA drug label explicitly warns against combining tranexamic acid with hormonal contraceptives, categorizing them as pro-thrombotic medical products that can further increase thromboembolic risk 3. Combined oral contraceptives themselves carry VTE risk, particularly those containing ethinylestradiol, which induces resistance to activated protein C 4.
Standard Dosing Regimen
For Heavy Menstrual Bleeding:
- Total daily dose: 3.9-4 grams per day 1, 2, 5
- Duration: 4-5 days per menstrual cycle, starting on day 1 of bleeding 1, 2
- Typical regimen: 1.3 grams three times daily (or 650 mg six times daily to reach 3.9g) 1, 5
This dosing reduces menstrual blood loss by 26-60% and is significantly more effective than placebo, NSAIDs, or oral progestins 2, 5. In clinical trials, 81% of women were satisfied with this regimen, and 94% reported decreased menstrual blood loss 5.
Dose Adjustments for Renal Impairment
If the patient has renal dysfunction, reduce the dose according to serum creatinine 3:
- Creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
- Creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
- Creatinine >5.66 mg/dL: 10 mg/kg every 48 hours or 5 mg/kg every 24 hours
Safety Profile
The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea), occurring in approximately 12% of patients, which is comparable to placebo 5. Adverse events are generally mild to moderate in severity 1.
Contraindications include 3:
- Active intravascular clotting
- History of thrombosis or thromboembolism
- Subarachnoid hemorrhage
- Severe hypersensitivity to tranexamic acid
Clinical Decision Algorithm
If the patient is currently taking combined oral contraceptives:
- Stop tranexamic acid immediately or choose an alternative contraceptive method 3
- Consider alternative treatments for heavy menstrual bleeding such as NSAIDs (mefenamic acid), levonorgestrel-releasing IUD, or progestin-only options 2, 5
If not on hormonal contraceptives: